Cell type-associated traits map for the [Lake_2017_VisualCortex_Excitatory neuron 6a][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [Lake_2017_VisualCortex_Excitatory neuron 6a]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 5.00e-2 | 1.63e-2 |
ADHD | Attention Deficit Hyperactivity Disorder | MTC | Middeldorp | 2016 | NA | 17666 | 5.00e-2 | 2.45e-2 |
Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-3 | 1.18e-2 |
Anorexia Nervosa | Anorexia Nervosa | MTC | Boraska | 2014 | 2907 | 14860 | 1.00e-2 | 3.27e-2 |
Anorexia Nervosa | Anorexia Nervosa | MTC | Duncan | 2017 | 3495 | 10982 | 1.00e-2 | 2.39e-2 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 5.00e-2 | 6.43e-3 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 5.00e-2 | 2.41e-5 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-2 | 9.11e-4 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-3 | 4.04e-2 |
Birth Weight | Birth Weight | MTC | Horikoshi | 2013 | NA | 26836 | 5.00e-2 | 4.09e-2 |
Birth Weight | Birth Weight | MTC | Horikoshi | 2013 | NA | 26836 | 1.00e-2 | 1.44e-2 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 3.89e-2 |
Clozapine Induced Agranulocytosis | Clozapine Induced Agranulocytosis | ETC | Goldstein | 2014 | 161 | 1196 | 5.00e-2 | 9.90e-3 |
CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 5.00e-2 | 1.86e-2 |
CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 1.00e-3 | 3.37e-2 |
CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 1.00e-4 | 1.88e-2 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 5.00e-2 | 1.58e-3 |
Depressive Symptoms | Depressive Symptoms | ETC | Okbay | 2016 | 122210 | 58835 | 1.00e-3 | 3.83e-2 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 2.56e-2 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-2 | 2.56e-2 |
Gait Speed | Gait Speed | MTC | Ben-Avraham | 2017 | NA | 31478 | 5.00e-2 | 8.00e-3 |
Gait Speed | Gait Speed | MTC | Ben-Avraham | 2017 | NA | 31478 | 1.00e-2 | 2.07e-2 |
Insomnia | Insomnia | MTC | Hammerschlag | 2017 | 12863 | 40776 | 1.00e-4 | 3.96e-2 |
Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 1.00e-3 | 3.55e-2 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 5.00e-2 | 4.92e-2 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 1.00e-2 | 1.42e-2 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-2 | 8.07e-5 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-3 | 2.11e-3 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-4 | 3.17e-2 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-5 | 2.07e-2 |
Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 5.00e-2 | 4.28e-2 |
Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 1.00e-2 | 2.02e-2 |
Obesity Childhood | Obesity Childhood | MTC | Bradfield | 2012 | 5530 | 8318 | 5.00e-2 | 4.25e-2 |
Partial Epilepsy | Partial Epilepsy | MTC | Kasperaviciute | 2010 | 3445 | 6935 | 5.00e-2 | 2.56e-2 |
Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 5.00e-2 | 5.01e-3 |
Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-2 | 2.83e-2 |
Sleep Duration | Sleep Duration | MTC | Marinelli | 2016 | NA | 10554 | 5.00e-2 | 3.91e-2 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 5.00e-2 | 1.16e-2 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 1.00e-2 | 3.17e-2 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 1.00e-3 | 1.17e-2 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 4.50e-3 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 1.00e-2 | 3.05e-2 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 1.00e-3 | 2.25e-3 |
Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 1.00e-2 | 2.97e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 1.00e-2 | 1.70e-2 |
Alcohol Consumption | Alcohol Consumption All Continuous | MTC | Schumann | 2016 | NA | 70460 | 1.00e-2 | 3.39e-2 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 5.00e-2 | 1.18e-2 |
Alcohol Consumption | Alcohol Consumption Men Continuous | MTC | Schumann | 2016 | NA | 27560 | 5.00e-2 | 3.62e-2 |
Alcohol Consumption | Alcohol Consumption Men Dichotomous | MTC | Schumann | 2016 | NA | 26991 | 1.00e-3 | 2.21e-2 |
Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 5.00e-2 | 1.02e-2 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 1.00e-3 | 2.58e-2 |
Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 1.77e-3 |
Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 2.48e-3 |
Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 1.00e-2 | 3.29e-3 |
Anthropometric Extremes | Obesity Class 2 | MTC | Berndt | 2013 | 9889 | 65840 | 1.00e-5 | 2.89e-2 |
Anthropometrics Sex Stratified | Body Mass Index Men | MTC | Randall | 2013 | 60586 | 60856 | 1.00e-4 | 4.44e-2 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 5.00e-2 | 3.11e-2 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-3 | 4.44e-2 |
Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 5.00e-2 | 2.48e-2 |
Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 1.00e-3 | 2.62e-2 |
Blood Cells | Basophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.77e-3 |
Blood Cells | Basophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.13e-2 |
Blood Cells | Basophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 4.37e-2 |
Blood Cells | Mean Corpuscular Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.68e-2 |
BMI Age Stratified | BMI Men Age Over 50 | MTC | Winkler | 2015 | NA | 90988 | 5.00e-2 | 1.59e-2 |
BMI Age Stratified | BMI Men Age Over 50 | MTC | Winkler | 2015 | NA | 90988 | 1.00e-2 | 4.56e-2 |
BMI Age Stratified | BMI Men Age Over 50 | MTC | Winkler | 2015 | NA | 90988 | 1.00e-5 | 2.95e-2 |
BMI Age Stratified | BMI Women Age Over 50 | MTC | Winkler | 2015 | NA | 106622 | 1.00e-2 | 2.33e-2 |
BMI Age Stratified | BMI Women Age Over 50 | MTC | Winkler | 2015 | NA | 106622 | 1.00e-3 | 4.20e-2 |
BMI Physical Activity Interaction | BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.76e-2 |
BMI Physical Activity Interaction | BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 2.05e-2 |
BMI Physical Activity Interaction | BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.55e-2 |
BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.61e-2 |
BMI Physical Activity Interaction | BMI Inactive European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 4.00e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-5 | 1.88e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 3.46e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 2.62e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-5 | 2.21e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 6.44e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 3.96e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 3.37e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.97e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 6.36e-3 |
BMI Smoking Adjusted | BMI Smoking Adjusted Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 2.41e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 2.97e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.66e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 5.00e-2 | 1.72e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 3.45e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 5.00e-2 | 7.54e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-2 | 1.27e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 4.71e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7050 | 5.00e-2 | 2.06e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7432 | 5.00e-2 | 6.66e-3 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-2 | 2.52e-3 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-3 | 1.50e-2 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-5 | 2.47e-2 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 1.58e-2 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 2.08e-3 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 3.47e-3 |
Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.97e-2 |
Facial Shape | Mod20 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.78e-2 |
Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.25e-3 |
Facial Shape | Mod39 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.35e-2 |
Facial Shape | Mod55 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.20e-2 |
Facial Shape | Mod55 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.33e-2 |
Forced Expiratory Volume | Forced Expiratory Volume Over Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 2.37e-2 |
Glucose Stimulated Insulin Secretion | Corrected Insulin Response | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 8.15e-3 |
Glucose Stimulated Insulin Secretion | Incremental Insulin At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 5.33e-3 |
Glucose Stimulated Insulin Secretion | Incremental Insulin At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 1.54e-2 |
Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 2.75e-2 |
Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 2.72e-3 |
Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes Corrected For BMI | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.54e-3 |
Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes Corrected For BMI | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 2.80e-2 |
Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.28e-3 |
Glycemic Traits BMI Corrected | Fasting Glucose Interaction With BMI | MTC | Manning | 2012 | NA | 58074 | 5.00e-2 | 5.04e-3 |
Glycemic Traits BMI Corrected | Fasting Insulin | MTC | Manning | 2012 | NA | 51750 | 5.00e-2 | 2.32e-2 |
Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-2 | 6.36e-3 |
Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-3 | 2.89e-2 |
Kidney Function | Chronic Kidney Disease | MTC | Kottgen | 2010 | NA | 67093 | 5.00e-2 | 3.93e-2 |
Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 5.00e-2 | 4.63e-2 |
Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 1.00e-3 | 4.37e-2 |
Lymphocyte Subsets | CD19 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 2.72e-2 |
Personality Big5 | Openness To Experience | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 4.17e-2 |
Reproductive Behavior | Age First Birth Female | MTC | Barban | 2016 | NA | 189656 | 5.00e-2 | 2.21e-2 |
Reproductive Behavior | Age First Birth Female | MTC | Barban | 2016 | NA | 189656 | 1.00e-2 | 2.59e-2 |
Reproductive Behavior | Age First Birth Male | MTC | Barban | 2016 | NA | 48408 | 1.00e-3 | 1.54e-2 |
Reproductive Behavior | Age First Birth Pooled | ETC | Barban | 2016 | NA | 238064 | 5.00e-2 | 6.78e-3 |
Reproductive Behavior | Age First Birth Pooled | ETC | Barban | 2016 | NA | 238064 | 1.00e-2 | 3.01e-2 |
Reproductive Behavior | Number Children Even Born Pooled | MTC | Barban | 2016 | NA | 329139 | 1.00e-3 | 3.80e-2 |
Reproductive Behavior | Number Children Ever Born Female | MTC | Barban | 2016 | NA | 225230 | 5.00e-2 | 3.37e-2 |
Shoulder Dislocation | Shoulder Dislocation, European Or Latino | MTC | Kim | 2017 | 662 | 82602 | 1.00e-3 | 3.40e-2 |
Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 1.00e-3 | 1.92e-2 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 1.00e-4 | 2.70e-2 |
Circadian Rhythm | Sleep Chronotype | MTC | Jones | 2016 | NA | 127898 | 5.00e-2 | 1.15e-2 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 6.25e-5 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 1.00e-2 | 2.56e-2 |
Statin Efficacy | Delta LDL With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 2.64e-2 |
Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 1.61e-2 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 5.00e-2 | 2.44e-3 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-2 | 2.53e-2 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-3 | 1.78e-2 |
Waist Format 1 | Waist Circumference European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 1.94e-2 |
Waist Format 1 | Waist Circumference European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 8.20e-3 |
Waist Format 1 | Waist Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 3.05e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-5 | 7.93e-3 |
BIP | Bipolar disorder | ETC | Stahl | 2018 | 20352 | 31358 | 5.00e-2 | 1.82e-2 |
BIP | Bipolar disorder | ETC | Stahl | 2018 | 20352 | 31358 | 1.00e-4 | 9.35e-3 |
BIP | Bipolar disorder | ETC | Stahl | 2018 | 20352 | 31358 | 1.00e-5 | 5.07e-4 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-2 | 1.82e-2 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-4 | 2.07e-2 |
PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 5.00e-2 | 4.79e-2 |
COL | SSGAC_College | ETC | Rietveld | 2013 | NA | 101069 | 1.00e-2 | 1.01e-2 |
COL | SSGAC_College | ETC | Rietveld | 2013 | NA | 101069 | 1.00e-3 | 3.65e-2 |
T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 5.00e-2 | 1.20e-2 |
T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-2 | 3.96e-3 |
AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 5.00e-2 | 4.38e-2 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-3 | 2.14e-2 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 5.00e-2 | 2.86e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 2.04e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 7.74e-3 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 5.00e-2 | 1.07e-2 |
Sleep | Sleep time to midpoint | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 2.57e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 6.35e-3 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 1.29e-2 |
Facial attractiveness | Facial attractiveness of females, female raters | ETC | Hu | 2019 | NA | 2062 | 1.00e-2 | 3.59e-2 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-2 | 5.16e-3 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-3 | 2.39e-3 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-4 | 2.17e-2 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-5 | 1.07e-2 |
K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 5.00e-2 | 1.76e-2 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 5.00e-2 | 7.10e-3 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 1.00e-2 | 4.32e-3 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 5.00e-2 | 9.46e-3 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-2 | 2.72e-2 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-2 | 2.85e-2 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-2 | 4.71e-2 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-2 | 9.54e-3 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-3 | 3.03e-2 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-4 | 2.79e-2 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-5 | 1.12e-2 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-3 | 2.70e-3 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-4 | 2.44e-2 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-5 | 1.22e-2 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-2 | 7.79e-4 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-4 | 4.11e-2 |
Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 1.00e-2 | 2.51e-2 |
Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 1.00e-3 | 1.49e-2 |
Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 5.00e-2 | 4.11e-2 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-2 | 9.39e-5 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-3 | 2.41e-3 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-5 | 2.60e-2 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 5.00e-2 | 6.22e-3 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-2 | 3.79e-2 |
Smoking | Smoking behaviour, cigarettes smoked per day | ETC | Liua | 2019 | NA | 377334 | 1.00e-2 | 3.85e-2 |
Smoking | Age of smoking initiation | ETC | Liua | 2019 | NA | 341427 | 5.00e-2 | 1.95e-2 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 5.00e-2 | 2.92e-2 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-2 | 5.14e-3 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-3 | 3.79e-2 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 1.42e-3 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 1.38e-2 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 4.47e-2 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 2.83e-3 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-4 | 2.90e-2 |
Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 2.78e-2 |
Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 4.21e-2 |
Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-4 | 6.59e-3 |
Hippocampal volume | Hippocampal tail volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.51e-2 |
Hippocampal volume | Total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.00e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.59e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 5.45e-3 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 5.00e-2 | 1.84e-2 |
AUDIT-C | Alcohol-Use-Disorder-Identification-Test-Consumption | ETC | Kranzler | 2019 | NA | 200680 | 5.00e-2 | 8.21e-4 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 3.44e-3 |
Medication use | Medication use (vasodilators used in cardiac diseases) | ETC | Wu Y | 2019 | 5,546 | 237,113 | 5.00e-2 | 4.89e-2 |
Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 5.00e-2 | 3.30e-2 |
Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 5.00e-2 | 4.57e-2 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 5.00e-2 | 4.34e-2 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 5.00e-2 | 3.02e-3 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 1.00e-2 | 2.35e-2 |
Renal cell carcinoma | Renal cell carcinoma female | ETC | Laskar RS | 2019 | 1,992 | 3,095 | 1.00e-3 | 2.15e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 1.25e-5 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 4.44e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 2.21e-2 |
Nonalcoholic Liver disease | Liver fibrosis in non-alcoholic fatty acid liver disease | ETC | Namjou B | 2019 | NA | 235 | 1.00e-2 | 3.63e-2 |
Autistic traits score | Autistic traits score (Social and Communication Disorders Checklist) | ETC | Massrali A | 2019 | NA | 5,628 | 5.00e-2 | 2.02e-2 |
Autistic traits score | Autistic traits score (Social and Communication Disorders Checklist) | ETC | Massrali A | 2019 | NA | 5,628 | 1.00e-2 | 2.91e-4 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-2 | 8.03e-4 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-3 | 5.50e-4 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-4 | 4.52e-2 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-2 | 1.41e-3 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-3 | 1.53e-3 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-4 | 9.92e-3 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-5 | 1.98e-2 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 5.00e-2 | 8.14e-5 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-2 | 1.50e-3 |
same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 5.00e-2 | 1.29e-3 |
same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 1.00e-2 | 2.90e-2 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 5.00e-2 | 2.44e-3 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 1.99e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-2 | 1.14e-4 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-3 | 4.48e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-4 | 3.50e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-2 | 3.28e-4 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-3 | 1.43e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-4 | 1.60e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-3 | 3.73e-4 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-4 | 4.54e-4 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-5 | 2.35e-3 |
Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 1.00e-2 | 8.67e-4 |
Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 1.00e-3 | 2.30e-2 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-2 | 4.46e-3 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-3 | 2.62e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-4 | 2.38e-4 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-5 | 1.60e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-2 | 1.74e-3 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 374,756 | 1.00e-3 | 1.09e-4 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 374,756 | 1.00e-4 | 1.42e-2 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 374,756 | 1.00e-5 | 2.05e-2 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 434,794 | 1.00e-4 | 4.44e-3 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 434,794 | 1.00e-5 | 6.10e-3 |
Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 5.00e-2 | 1.14e-3 |
Lung function | Lung function (forced vital capacity) variance | ETC | Wang H | 2019 | NA | 317,222 | 1.00e-2 | 4.87e-2 |
BMI by age | BMI at 6 months old | ETC | Helgeland O | 2019 | NA | 8,017 | 5.00e-2 | 2.26e-2 |
BMI by age | BMI at 6 months old | ETC | Helgeland O | 2019 | NA | 8,017 | 1.00e-2 | 2.87e-2 |
BMI by age | BMI at 6 months old | ETC | Helgeland O | 2019 | NA | 8,017 | 1.00e-4 | 2.58e-2 |
BMI by age | BMI at 8 months old | ETC | Helgeland O | 2019 | NA | 7,197 | 5.00e-2 | 7.83e-3 |
BMI by age | BMI at 8 months old | ETC | Helgeland O | 2019 | NA | 7,197 | 1.00e-2 | 9.31e-4 |
BMI by age | BMI at 8 months old | ETC | Helgeland O | 2019 | NA | 7,197 | 1.00e-3 | 4.46e-3 |
BMI by age | BMI at 1 year old | ETC | Helgeland O | 2019 | NA | 6,970 | 5.00e-2 | 2.44e-3 |
BMI by age | BMI at 1 year old | ETC | Helgeland O | 2019 | NA | 6,970 | 1.00e-2 | 1.10e-2 |
BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 5.00e-2 | 1.58e-2 |
BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 1.00e-2 | 1.06e-2 |
BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 5.00e-2 | 3.32e-2 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-3 | 8.68e-3 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 2.18e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-3 | 4.87e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 5.00e-2 | 1.44e-2 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-2 | 1.98e-2 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-3 | 4.94e-3 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-4 | 1.79e-2 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-2 | 1.23e-2 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-3 | 1.44e-2 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-4 | 4.95e-2 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-5 | 1.74e-2 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 5.00e-2 | 2.21e-4 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-2 | 9.12e-4 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-3 | 1.62e-2 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-4 | 9.35e-3 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-2 | 1.84e-5 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-3 | 1.96e-5 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-4 | 4.03e-2 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-5 | 2.02e-2 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 6.62e-3 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-2 | 2.65e-4 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-3 | 7.55e-3 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 5.00e-2 | 9.89e-4 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-2 | 7.34e-4 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-3 | 2.99e-2 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 5.00e-2 | 3.63e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-5 | 4.90e-2 |
COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 5.00e-2 | 6.22e-3 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.